Entrepreneurship
"We promote the generation of new companies through collaboration with biotechnology companies, pharmaceutical companies and investment funds to facilitate the arrival of our scientific discoveries to the patient".
LUCIA VANRELL
HEAD OF TRANSLATION AND INNOVATION
Our licensed products seek to solve unmet medical needs in the treatment of rare, neurological, oncological and cardiovascular diseases through gene therapy, cell therapy and therapeutic vaccines.
New spin-off companies and start-ups have emerged from Cima's research discoveries with the aim of reducing the risks associated with drug development and accelerating their access to market.
Need more information?
If you are interested in collaborating with us, please contact our Translation and Innovation Unit.
New companies
We develop pharmaceuticals that become solutions
Gene therapy for the treatment
of rare liver diseases
Biotechnology company associated with FIMA, Cima's holding company, to develop VTX-801, a viral vector for gene therapy aimed at treating alterations in the ATP7B gene, responsible for copper metabolism and whose mutation causes its accumulation in the liver and other tissues causing different diseases.
Antifibrinolytic strategy for the
treatment of hemorrhage
Biotechnology company promoted by Cima for the development of CM-352, a new proprietary compound to reduce bleeding in life-threatening and disabling hemorrhagic conditions associated with surgery, trauma, intracerebral hemorrhage (ICH) or other tissue damage.
New drug
testing models
MIMO (Modelling Immunotherapy In Oncology) Biosciences is focused on the development of immunotherapy in cancer. Its mission is to provide preclinical research services based on unique animal models that recapitulate a wide range of genetic alterations of different hematological malignancies, including multiple myeloma and lymphomas.
QimerBio Therapeutics
Biotech company, spin-off of Cima, the Clínica Universidad de Navarra and the University of Navarra. The main objective is the discovery and development of adoptive cell therapies, from proof-of-concept to clinical value stages, focusing on meeting unmet medical needs in the treatment of cancer and autoimmune diseases.